

Advances in Experimental Medicine and Biology

Volume 1049

Series editors

Irun R. Cohen, Rehovot, Israel
Abel Lajtha, Orangeburg, USA
John D. Lambris, Philadelphia, USA
Rodolfo Paoletti, Milan, Italy
Nima Rezaei, Tehran, Iran

More information about this series at <http://www.springer.com/series/5584>

Clévio Nóbrega · Luís Pereira de Almeida
Editors

Polyglutamine Disorders

 Springer

Editors

Clévio Nóbrega
Department of Biomedical Sciences and
Medicine, Centre for Biomedical
Research and Algarve Biomedical Center
University of Algarve
Faro
Portugal

Luís Pereira de Almeida
Center for Neuroscience and Cell Biology
and Faculty of Pharmacy
University of Coimbra
Coimbra
Portugal

ISSN 0065-2598 ISSN 2214-8019 (electronic)
Advances in Experimental Medicine and Biology
ISBN 978-3-319-71778-4 ISBN 978-3-319-71779-1 (eBook)
<https://doi.org/10.1007/978-3-319-71779-1>

Library of Congress Control Number: 2017960922

© Springer International Publishing AG 2018, corrected publication 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

On Polyglutamine Diseases

Polyglutamine (polyQ) diseases are a group of rare neurodegenerative disorders that share a common genetic cause: they arise as a result of abnormal expansions of CAG trinucleotide sequences occurring at particular genome loci. In contrast with other repeat-related disorders, the repeat-bearing tracts associated with polyQ diseases are present at the codifying region of genes, being translated as expanded polyQ tracts in their respective protein products. Although these genes and proteins are otherwise unrelated and share no significant homology outside the CAG/polyQ tract, proteins carrying an abnormally expanded polyQ tract tend to aggregate, forming insoluble protein aggregates that constitute a key neuropathological feature of polyQ disorders. The group currently includes nine disorders: Huntington's disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and six different types of spinocerebellar ataxia: SCA 1, 2, 3, 6, 7, and 17. PolyQ diseases are highly incapacitating and, to this date, no therapy able to modify disease progression is available for any of them.

PolyQ disorders share several features. These include (a) the existence of a positive correlation between the variable CAG repeat number and both the severity and precocity of symptoms; (b) the generational instability in CAG repeat number transmission; and (c) the aforementioned propensity for the protein products to aggregate and to constitute large intracellular multiprotein inclusions that are detected in patients' neuronal tissue. Despite the genetic cause of polyQ disorders being clearly identified, the molecular mechanisms involved in their pathogenesis are not fully understood. Though it is frequently accepted that these disorders share common pathogenic mechanisms, the symptoms and the regional patterns of neurodegeneration are not shared among disorders. Taken together, the similarities and differences existing in this group of disorders suggest that the search for disease mechanisms and putative therapeutic strategies will benefit from an integrative view that conjugates common factors and motifs with the particularities of each polyQ disease.

For this book entitled *Polyglutamine Disorders*, we have gathered many of the main experts around the world in the field, whom we would like to acknowledge for their work and collaboration, providing a state-of-the-art revision about several aspects of the different polyQ diseases. The book addresses the molecular mechanisms described to underlie disease pathogenesis, the animal models developed to study these diseases and, importantly, the advanced therapeutic strategies being investigated for these disorders.

Coimbra, Portugal
January 2018

Clévio Nóbrega
Luís Pereira de Almeida

Contents

1	Clinical Features of Huntington’s Disease	1
	Rhia Ghosh and Sarah J. Tabrizi	
2	Genetic Rodent Models of Huntington Disease	29
	J. Stricker-Shaver, A. Novati, L. Yu-Taeger and H. P. Nguyen	
3	Mitochondrial Dysfunction in Huntington’s Disease	59
	Catarina Carmo, Luana Naia, Carla Lopes and A. Cristina Rego	
4	RNA Related Pathology in Huntington’s Disease	85
	Andreas Neueder and Gillian P. Bates	
5	X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity	103
	Constanza J. Cortes and Albert R. La Spada	
6	Spinocerebellar Ataxia Type 1: Molecular Mechanisms of Neurodegeneration and Preclinical Studies	135
	Judit M. Pérez Ortiz and Harry T. Orr	
7	Spinocerebellar Ataxia Type 6: Molecular Mechanisms and Calcium Channel Genetics	147
	Xiaofei Du and Christopher Manuel Gomez	
8	Spinocerebellar Ataxia Type 2	175
	Daniel R. Scoles and Stefan M. Pulst	
9	Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7	197
	Alice Karam and Yvon Trottier	
10	Spinocerebellar Ataxia Type 17 (SCA17)	219
	Yasuko Toyoshima and Hitoshi Takahashi	

11 The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease	233
Arnulf H. Koeppen	
12 Origins and Spread of Machado-Joseph Disease Ancestral Mutations Events	243
Sandra Martins and Jorge Sequeiros	
13 Clinical Features of Machado-Joseph Disease	255
Nuno Mendonça, Marcondes C. França, Jr., António Freire Gonçalves and Cristina Januário	
14 Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease	275
Ana Luisa Carvalho, Alexandra Silva and Sandra Macedo-Ribeiro	
15 Animal Models of Machado-Joseph Disease	289
Jana Schmidt and Thorsten Schmidt	
16 Towards the Identification of Molecular Biomarkers of Spinocerebellar Ataxia Type 3 (SCA3)/Machado-Joseph Disease (MJD)	309
Manuela Lima and Mafalda Raposo	
17 Planning Future Clinical Trials for Machado-Joseph Disease	321
Jonas Alex Morales Saute and Laura Bannach Jardim	
18 Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis	349
Clévio Nóbrega, Ana Teresa Simões, Joana Duarte-Neves, Sónia Duarte, Ana Vasconcelos-Ferreira, Janete Cunha-Santos, Dina Pereira, Magda Santana, Cláudia Cavadas and Luís Pereira de Almeida	
19 Pharmacological Therapies for Machado-Joseph Disease	369
Sara Duarte-Silva and Patrícia Maciel	
20 Gene Therapies for Polyglutamine Diseases	395
Carlos A. Matos, Vítor Carmona, Udaya-Geetha Vijayakumar, Sara Lopes, Patrícia Albuquerque, Mariana Conceição, Rui Jorge Nobre, Clévio Nóbrega and Luís Pereira de Almeida	
21 Stem Cell-Based Therapies for Polyglutamine Diseases	439
Liliana S. Mendonça, Isabel Onofre, Catarina Oliveira Miranda, Rita Perfeito, Clévio Nóbrega and Luís Pereira de Almeida	
Erratum to: Spinocerebellar Ataxia Type 6: Molecular Mechanisms and Calcium Channel Genetics	E1
Xiaofei Du and Christopher Manuel Gomez	
Index	467